Personalis, Inc. (FRA:04X)

Market Cap	700.38M +96.3%
Revenue (ttm)	58.90M -21.0%
Net Income	-62.97M
EPS	-0.75
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	114
Open	8.07
Previous Close	8.17
Day's Range	8.07 - 8.07
52-Week Range	2.56 - 9.76
Beta	n/a
RSI	50.84
Earnings Date	Feb 27, 2026

About Personalis

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample....

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2011
• Employees: 229
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 04X

Financial Performance

In 2024, Personalis's revenue was $84.61 million, an increase of 15.15% compared to the previous year's $73.48 million. Losses were -$81.28 million, -24.94% less than in 2023.

Financial numbers in USD